Calls
Source: S&P Capital IQ transcripts via Xpressfeed · latest indexed call 2026-05-06 · generated 2026-07-28.
Latest call digest
Herbalife Ltd., Q1 2026 Earnings Call, May 06, 2026 · 2026-05-06T21:30:00
Q1 2026 call — May 6, 2026. Herbalife cleared both guidance ranges. Net sales of $1.3 billion rose 7.8% year-over-year and 5.4% in constant currency against a 3% to 7% guide, and adjusted EBITDA of $176 million came in above the $155 million to $175 million range. Management called it the third consecutive quarter of year-over-year growth and the strongest since the second quarter of 2021.
Prepared remarks were organised around personalization. The Bioniq acquisition closed April 30 for $55 million of base consideration payable over five years plus up to $95 million contingent; Pro2col was positioned as the operating system tying together Link BioScience, Bioniq and Pruvit; a multi-year repackaging programme began in March and runs to end-2027. The April $1.45 billion refinancing is expected to deliver roughly $45 million of annualised cash interest savings, and a new disclosure — net leverage of 2.1x, with a target below 2x by year-end — sat alongside the existing 2.7x total leverage ratio.
The composition of the beat matters more than the headline. Volume grew 4.1% worldwide, while pricing added about $40 million and FX about $29 million of the roughly $100 million net sales increase. India set a second consecutive record at $275 million, up 32% reported and 39% in local currency, on volume up 37%, following the September 2025 GST rate cut. Outside that, results were mixed: EMEA constant-currency sales fell 6% on an 11% volume decline, North America fell 3% on a 5% volume decline (attributed to severe January-February weather closing distributor-owned clubs and to shipments in transit at quarter end), and China fell 12% reported and 16% in local currency.
Q&A was narrower and more sceptical than the prepared remarks. Analysts asked for evidence of Pro2col adoption and got process description rather than metrics; management confirmed no direct Pro2col revenue is in the 2026 forecast, framing it as upside rather than risk. China was quantified at about 4% of sales with no strategy benefit in the numbers. EMEA weakness went largely unaddressed.
Guidance actually stated: Q2 reported net sales up 1.5% to 5.5% (1% to 5% constant currency) and adjusted EBITDA of $150 million to $170 million; full-year reported net sales up 1.5% to 5.5% and adjusted EBITDA of $675 million to $705 million; India GST net incremental cost of roughly $20 million to $25 million for the year; capital expenditure of $50 million to $80 million plus $35 million to $55 million of capitalised SaaS costs; adjusted effective tax rate around 30%.
Participant coverage from the latest call.
| Group | Participants | Count |
|---|---|---|
| Management | Operator; Erin Banyas — Head of Investor Relations, Herbalife Ltd.; Stephan Gratziani — Chief Executive Officer, Herbalife Ltd.; John DeSimone — Chief Financial Officer, Herbalife Ltd. | 4 |
| Analysts | Chasen Bender — Assistant Vice President, Citigroup Inc., Research Division; Karru Martinson — Analyst, Jefferies LLC, Research Division; Nicholas Sherwood — Research Analyst, Maxim Group LLC, Research Division; John Baumgartner — Former MD & Senior Consumer Equity Research Analyst, Mizuho Securities USA LLC, Research Division; Douglas Lane — Managing Director of Consumer, Water Tower Research LLC | 5 |
Curated latest-call exchanges; one row per analyst topic.
| Analyst | Firm | Topic | What changed in Q&A |
|---|---|---|---|
| Chasen Bender | Citigroup Inc., Research Division | Pro2col beta adoption evidence | Asked directly whether beta distributors are selling more Herbalife product and how long customers stay engaged with the app. The answer described the beta's expansion to ten EMEA markets and the feedback loop with distributors, without adoption, engagement or sales figures. DeSimone added that no direct Pro2col revenue is built into the forecast, so any result is upside rather than risk this year. |
| Chasen Bender | Citigroup Inc., Research Division | India GST tailwind and price elasticity elsewhere | Asked what India growth rate is embedded in guidance for the rest of the year. DeSimone declined to give an India figure, said Q2 through Q4 sales expectations are unchanged from February, and that growth will moderate after the September lapping while momentum continues. He extended the India lesson to price and commission testing in other markets, citing EMEA softness and a volume response to the Mexico price increase. |
| Karru Martinson | Jefferies LLC, Research Division | Higher oil costs and pass-through | Management is absorbing the cost rather than passing it to consumers and has not raised prices for it. Guidance carries only a preliminary estimate and management said the impact is not material to the year. Whether geopolitical disruption shifted ordering patterns was called too soon to tell, though European weakness was acknowledged without a cause attached. |
| Karru Martinson | Jefferies LLC, Research Division | China size and trajectory | DeSimone sized China at about 4% of sales with no meaningful profit contribution, said the market's planned strategies are not in the forecast and will not be until results appear, and described the business as not yet having found its footing. Gratziani pointed to distributors from Greater China entering the market for the first time and roughly 500 looking at building there. |
| Nicholas Sherwood | Maxim Group LLC, Research Division | Pro2col inside nutrition clubs | Asked for feedback from the club channel, which management describes as a consumption-driven business with millions of annual walk-ins. The integration is still being built and was characterised as a major work item at an early stage. |
| Nicholas Sherwood | Maxim Group LLC, Research Division | Preferred member migration to new commerce platform | The migration opened only recently after a small pilot, so management said it is too early to discuss. The one substantive datapoint offered was that subscription uptake on the new commerce platform has been positive; Bioniq in Europe will be the company's first genuine subscription product. |
| John Baumgartner | Mizuho Securities USA LLC, Research Division | EMEA: structural decline or productivity | Asked whether the consistent sales-leader declines in EMEA point to structural weakness in direct selling there or to a productivity problem that price adjustments could fix. The reply discussed how consumer expectations and the product offer must evolve and did not address the sales-leader trend or choose between the two explanations. |
| Douglas Lane | Water Tower Research LLC | Bioniq rollout, branding and Link BioScience timing | Bioniq's personalized vitamin and mineral offer will be essentially the same in Europe and the U.S. subject to regulatory differences, will be sold only through Herbalife distributors, and the brand is being retained with the reveal held for Extravaganza. Link BioScience product was placed in the first quarter of next year, a later date than the mid-2026 personalized-supplement access described on prior calls. |
| Douglas Lane | Water Tower Research LLC | Capital allocation after the refinancing | No change to priorities. The stated first priority remains reducing gross debt to approximately $1.4 billion by the end of 2028, which management said would put net debt below $1 billion. No buyback discussion was offered. |
Theme tracker
Themes are curator-classified across supplied calls.
| Theme | Status | Quarters mentioned | Read-through |
|---|---|---|---|
| Personalized nutrition platform (Pro2col, Link BioScience, Bioniq, Pruvit) | emerged | Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | Absent from calls before April 2025, then the organising idea of every call since. It has also become the dominant Q&A subject. The gap worth watching is that after five quarters it still carries no revenue in company guidance, and the Link BioScience product date has moved from the first half of 2026 to the first quarter of next year. |
| Debt reduction and leverage targets | persisted | Q2 2023, Q3 2023, Q4 2023, Q1 2024, Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | The most consistently delivered theme across the whole history. The target has been reset upward each time it was met: total leverage below 3x by end-2025 (hit in Q1 2025), then $1.4 billion of gross debt by 2028, then the April 2026 refinancing, and now a new net leverage measure with a sub-2x goal for year-end 2026. |
| Distributor recruiting rebuild (Premier League, Mastermind, Flex45) | persisted | Q1 2024, Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | Central to the 2024 story, when reversing twelve quarters of recruiting decline was the headline. Airtime has fallen steadily as the platform story took over, and on the latest call management said the Premier League comparison becomes less relevant going forward — retiring the metric that anchored the recovery narrative. |
| China turnaround | persisted | Q2 2023, Q3 2023, Q4 2023, Q1 2024, Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q3 2025, Q4 2025, Q1 2026 | Recurs on nearly every call, but the framing has weakened rather than improved: a customer loyalty programme and major growth opportunity in 2024, growth deferred to a 2027 event in February 2026, and by May 2026 a market at roughly 4% of sales that management says has not found its footing, with no benefit carried in guidance. |
| Nutrition club conversion from transactional to transformational | persisted | Q4 2023, Q2 2024, Q4 2024, Q1 2025, Q2 2025, Q1 2026 | The 1% to 2% conversion rate of club walk-ins to preferred customers has been described as a large untapped opportunity since 2023. Pro2col was presented in 2025 as the mechanism to raise it; on the latest call the club integration was still described as early. No updated conversion figure has been given. |
| GLP-1 positioning | dropped | Q2 2023, Q3 2023, Q4 2023, Q1 2024, Q3 2025 | A regular subject through early 2024, then largely absent. It resurfaced once in November 2025 as an analyst question, answered with unchanged framing (on-ramp, accompaniment, off-ramp, plus MultiBurn as a non-pharmaceutical alternative), and has not come up in the two calls since. The disappearance of a topic that once dominated the bear case is itself notable. |
| Tariffs | dropped | Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025 | Featured in guidance commentary on five consecutive calls, always characterised as immaterial after duty drawback. It is absent from the Q1 2026 call, where higher oil prices and the geopolitical environment took its place as the named external variable. One quarter of absence, so this reads as a substitution of risk vocabulary rather than a resolved issue. |
| India GST rate reduction as a demand driver | emerged | Q4 2025, Q1 2026 | New since the September 2025 rate cut and now the single largest swing factor in results. It cuts both ways: it drove record India quarters and the Q1 2026 beat, but the unchanged 18% rate on services created a cost mismatch whose estimated full-year drag rose from about $16 million in February to $20 million to $25 million in May. |
| Subscription revenue | emerged | Q2 2025, Q3 2025, Q1 2026 | Introduced with MultiBurn's automatic monthly option in July 2025 and repeatedly described as a structural gap the company is closing. Still qualitative — no subscriber count, retention rate or revenue contribution has been disclosed in any quarter. |
Guidance ledger
Quotes, calls, and speakers are source-verified; outcomes are curator-classified.
| Verbatim guidance | Call | Speaker | Curator outcome | Outcome note |
|---|---|---|---|---|
| “we further reduced our total leverage ratio to 3.5x as of June 30, with the goal to achieve our target of 3x by the end of 2025, following the repayment of the 2025 bonds” | Herbalife Ltd., Q2 2024 Earnings Call, Jul 31, 2024 · 2024-07-31T21:30:00 | John DeSimone | kept | Total leverage reached 3x as of March 31, 2025, which management described on the Q1 2025 call as reaching the milestone three quarters early. |
| “and we plan to use these cash flows to reduce debt by $1 billion over the next 4-plus years and believe we can accomplish this goal by the end of 2028” | Herbalife Ltd., Q3 2024 Earnings Call, Oct 30, 2024 · 2024-10-30T21:30:00 | John DeSimone | pending | Reaffirmed on every subsequent call. Nearly $540 million of debt had been repaid since the start of 2024 as of the Q1 2026 call; the 2028 target date has not passed. |
| “We expect adjusted EBITDA to be in the range of $600 million to $640 million, while in the range of $670 million to $710 million on a constant currency basis.” | Herbalife Ltd., Q4 2024 Earnings Call, Feb 19, 2025 · 2025-02-19T22:30:00 | John DeSimone | kept | Full year 2025 adjusted EBITDA was $658 million, above this initial reported range. The range was raised at each of the following three calls. |
| “By the end of 2025, we believe we'll have tens of thousands of users on the platform with hundreds of thousands by the end of next year.” | Herbalife Ltd., Q1 2025 Earnings Call, Apr 30, 2025 · 2025-04-30T21:30:00 | Stephan Gratziani | unknown | Later calls disclosed beta participation (just over 7,000 distributors in July 2025, growing to 7,900 by November) and engagement activity, but no platform user total against which this can be checked. |
| “We expect net sales growth in the third quarter of between 0.5% and 4.5% year-over-year, both on a reported and constant currency basis.” | Herbalife Ltd., Q2 2025 Earnings Call, Aug 06, 2025 · 2025-08-06T21:30:00 | John DeSimone | kept | Q3 2025 net sales rose 2.7% reported and 3.2% in constant currency, inside the range on both measures. |
| “We expect adjusted EBITDA for the fourth quarter to be in the range of $144 million to $154 million, while in the range of $154 million to $164 million on a constant currency basis.” | Herbalife Ltd., Q3 2025 Earnings Call, Nov 05, 2025 · 2025-11-05T22:30:00 | John DeSimone | kept | Q4 2025 adjusted EBITDA was $156 million, above the high end of the reported range. |
| “On a reported basis, we expect first quarter net sales growth of 3% to 7% year-over-year, including an approximately 250 basis point tailwind from currency.” | Herbalife Ltd., Q4 2025 Earnings Call, Feb 18, 2026 · 2026-02-18T22:30:00 | John DeSimone | kept | Q1 2026 reported net sales rose 7.8%, above the high end, with FX contributing an approximately 240 basis point tailwind. |
| “We expect full year adjusted EBITDA to be in the range of $675 million to $705 million on both a reported and constant currency basis.” | Herbalife Ltd., Q1 2026 Earnings Call, May 06, 2026 · 2026-05-06T21:30:00 | John DeSimone | pending | Narrowed from the $670 million to $710 million range given in February, with the constant currency midpoint raised. The year is not complete. |
| “we now expect India GST-related net incremental cost to be an approximately $20 million to $25 million headwind to full year adjusted EBITDA and an approximately 40 to 50 basis point headwind to adjusted EBITDA margin” | Herbalife Ltd., Q1 2026 Earnings Call, May 06, 2026 · 2026-05-06T21:30:00 | John DeSimone | pending | Higher than the roughly $16 million net incremental cost described on the February 2026 call, reflecting stronger India volume. The full-year figure is not yet testable. |
| “we are targeting net leverage to be below 2x by the end of '26 and remain on track to reduce outstanding debt to approximately $1.4 billion by the end of 2028” | Herbalife Ltd., Q1 2026 Earnings Call, May 06, 2026 · 2026-05-06T21:30:00 | John DeSimone | pending | Net leverage stood at 2.1x at March 31, 2026, the first quarter this measure was disclosed. Neither target date has passed. |
Q&A pressure map
Question counts and firms are curator tallies; analyst coverage shown above.
| Topic | Questions | Firms | Pressure / response |
|---|---|---|---|
| Pro2col and the personalization acquisitions: what they earn and when | 22 | Citigroup Inc., Research Division, Water Tower Research LLC, Mizuho Securities USA LLC, Research Division, Barclays Bank PLC, Research Division, Maxim Group LLC, Research Division | The dominant line of questioning on all five calls since the April 2025 acquisitions, spanning monetization model, guidance contribution, capital requirement, rollout pace, club integration and product segmentation. Management has answered the strategy questions fully and the economics questions sparingly. The most direct request for evidence — on the latest call, whether beta distributors sell more product and how long customers stay engaged — was met with a description of the beta process rather than adoption data, a step back from the engagement statistics volunteered in November 2025. |
| Debt paydown, leverage and use of excess cash | 13 | Barclays Bank PLC, Research Division, Jefferies LLC, Research Division, BofA Securities, Research Division, Water Tower Research LLC | Persistent across eight calls, and the topic where management has been most specific and most consistent. Buyback questions in November 2025 were answered plainly in the negative, and the answer did not change after the April 2026 refinancing removed the cost-of-debt argument. |
| North America return to growth and nutrition club conversion | 9 | B. Riley Securities, Inc., Research Division, Citigroup Inc., Research Division, BofA Securities, Research Division, Mizuho Securities USA LLC, Research Division, Water Tower Research LLC | Pressed hard through 2024 and early 2025 while the region declined, answered each time with a distributor-funnel rebuild argument and quarter-by-quarter framing. The pressure eased once North America returned to growth in Q3 2025, and the Q1 2026 decline was explained by weather and shipment timing rather than reopening the question. |
| Guidance conservatism and the pattern of beats | 7 | Citigroup Inc., Research Division, D.A. Davidson & Co., Research Division, Mizuho Securities USA LLC, Research Division | Analysts have repeatedly asked why raises lag the beats, why range midpoints move down when trends look better, and — in February 2026 — why margin expansion guidance looks light after eight consecutive quarters of exceeding quarterly guidance. Answers have generally identified a specific offset (FX translation lag on gross profit, the India GST services mismatch) rather than defending the range width. |
| China trajectory | 6 | D.A. Davidson & Co., Research Division, Citigroup Inc., Research Division, Jefferies LLC, Research Division | Raised on most calls since mid-2024, usually because results came in below expectations. Management's answers have consistently paired a long-term opportunity argument with an explicit refusal to put any of it in the forecast, which is unusually candid but leaves analysts without a timeline. |
| India GST tailwind durability | 3 | Citigroup Inc., Research Division, Mizuho Securities USA LLC, Research Division | New in February 2026 and immediately central, since India drove both recent beats. Management has said the tailwind runs until the late-September 2026 lapping and that momentum continues beyond at a more moderate level, but has declined to quantify India growth inside guidance. |
Language shifts
Only language evidence verified against the referenced component is shown.
| Observation | Verbatim evidence | Call ID | Component |
|---|---|---|---|
| The China framing has moved from opportunity language to plain admission of failure to execute. In October 2024 management called China a major growth opportunity being reshaped by a new customer loyalty programme; by May 2026 the CFO sized it at about 4% of sales and said the company has not found its footing, while keeping the long-term opportunity claim. | “We haven't found our footing yet.” | 1992814333 | 17 |
| Management retired the metric that anchored the two-year distributor recovery story, on the same call it cited a 13% two-year stack improvement from it. This is the second such retirement in the history reviewed and both followed the metric becoming harder to read favourably. | “And as we have now moved beyond the 2 year anniversary of the Premier League launch, this metric becomes less relevant going forward.” | 1992814333 | 3 |
| The precedent for that retirement: in February 2025 the company signalled it would stop reporting volume points after market-specific changes made year-over-year comparisons less meaningful. | “In future periods, it is likely we will stop reporting volume points and focus primarily on net sales.” | 1914847455 | 4 |
| The named external risk in guidance changed. Tariffs appeared in guidance commentary on five consecutive calls from February 2025 and are absent from the Q1 2026 call, replaced by oil prices and a volatile geopolitical environment. The hedging construction is identical to the one previously applied to tariffs. | “Our guidance also includes a preliminary estimate of the impact of higher oil prices.” | 1992814333 | 3 |
| The caveat that the strategic acquisitions carry no revenue in guidance has been repeated at every call since April 2025 and is now stated proactively rather than in response to a question. It is consistent and honest, but after five quarters it also means the personalization story remains untested against reported numbers. | “we have not rolled into our forecast any revenue – direct revenue from this” | 1992814333 | 7 |
| Confidence language stepped up in November 2025 and has stayed there. The August 2025 call still qualified progress as taking time to show in sales; from Q3 2025 onward management has used turning-the-corner and fundamentally-stronger constructions, which the subsequent three quarters of growth have so far supported. | “This quarter, we made great progress against our strategy and we're turning the corner.” | 1962738735 | 2 |
Twelve quarters of transcripts show a company that has done what it promised on the balance sheet and, since mid-2025, on the top line. The open question the calls leave is what is driving that growth: the Q1 2026 beat rests heavily on India's GST-driven price cut, on pricing and on currency, while the four acquisitions carrying the equity story still contribute no revenue in the company's own forecast and EMEA volume is falling. Whether India can hold after the September lapping, and whether personalization converts from strategy to revenue, is where the debate now sits.